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The tranSMART Foundation's inaugural Datathon took place June
30–July 2 at the Thomson Reuters ofﬁces in Boston, MA. The overall
aim of the Datathon was to determine the feasibility of using the
tranSMART platform to exploremultiple large datasets on a customized
cloud server to support a Datathon that could generate new research
ﬁndings. The goal of this Datathonwas to identify similarities and differ-
ences across different neurodegenerative diseases, speciﬁcally
Alzheimer's disease and Parkinson's disease, and to discover new in-
sights into these diseases.
Speciﬁc objectives were to identify:
• Common biomarker changes across Parkinson and Alzheimer
disease
• Common pathway changes across Parkinson and Alzheimer
disease
• The normal distribution of imaging and ﬂuid biomarkers across
controls
• Novel hypotheses, research ﬁndings or conclusions about these
neurodegenerative diseases.2. Design
The tranSMART Foundation, the Michael J. Fox Foundation, the
University of Luxembourg and the University of Michigan worked
together with the Laboratory of Neuro Imaging (LONI) to install
tranSMART v1.2.4 on cloud servers at LONI, and to install the 14datasets
to be used for the Datathon. The ADNI, PPMI, LRRK2 and BioFIND
datasets were curated and loaded by Thomson Reuters, working
with the Michael J. Fox Foundation. Due to restrictions on access to
and redistribution of the ADNI, PPMI, LRRK2 and BioFIND datasets,
data use agreements were executed with the Alzheimer's Data Neuro-
imaging Initiative, the Parkinson's Progression Markers Initiative,
the LRRK2 dataset, led by the Michael J. Fox foundation, and the
BIOFIND dataset. Ten datasets that were curated and loaded by the
University of Luxembourg originated in GEO, and did not require any
data use agreements. This Datathon marked the ﬁrst time that these
datasets have beenmade available in a single analytic platform. Togeth-
er the datasets represent over $500 million investment in data
generation.http://dx.doi.org/10.1016/j.atg.2015.08.004
2212-0661/© 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND licenseADNI: The Alzheimer's Disease Neuroimaging Initiative (ADNI) is
a longitudinal, multicenter study to develop genetic, biochemical,
clinical, and imaging biomarkers for the early detection and progres-
sion tracking of Alzheimer's disease. 3142 patients are currently
enrolled.
PPMI: The Parkinson's Progression Markers Initiative is a longitudi-
nal, multimodal observational study of a large patient population. The
dataset contains biological sampling, advanced imaging, clinical and be-
havioral assessments; i.e. the Movement Disorder Society—Uniﬁed
Parkinson's Disease Rating Scales (MD-UPDRS), Montreal Cognitive
Assessment (MoCA) and the University of Pennsylvania Smell Identiﬁ-
cation (UPSIT). 1334 patients are currently enrolled.
LRRK2: Michael J. Fox Foundation has established a LRRK2 Cohort
Consortium to undertake an innovative approach to design and stream-
line drugdevelopment around the LRRK2gene, a promising target. 2824
patients are currently enrolled.
BIOFIND: is a clinical observational study designed to discover and
validate novel biomarkers for Parkinson's disease. 229 patients are
currently enrolled.
10 Parkinson's Disease (PD) studies from GEO: The NCBI Gene Ex-
pression Omnibus (GEO—http://www.ncbi.nlm.nig.gov/). In attempt
to exact valuable knowledge, data scientists from the Luxembourg
Centre for Systems Biomedicine (http://wwwen.uni.lu/lcsb), Uni-
versity of Luxembourg (http://wwwen.uni.lu) manually curated 10
PD studies from GEO, which are selected based on having good
amount of clinical data apart from gene expression data. These stud-
ies were curated in the context of ongoing Innovative Medicine Initi-
ate (IMI) project and eTRIKS (http://www.etriks.org). Data from
these studies were passed through following workﬂow: data acquisi-
tion, parsing, manual inspections, data standardization, semantic align-
ment and mapping, the generated structured ﬁles are ready to be used
as input for the tranSMART ETL (Extraction, Transformation and Loading)
operations. The structured ﬁles were loaded into tranSMART using the
Pentaho Kettle ETL scripts.
The tranSMART Foundation, working with the University of
Michigan and LONI, installed the platform on LONI cloud servers, and
coordinated the installation of the curated datasets onto these servers
with ThomsonReuters, theMichael J. Fox Foundation and theUniversity
of Luxembourg. The latest tranSMART platform, v1.2.4, was employed
for these efforts. Access to the databases permitted participants to
evaluate whether modiﬁcations were needed to make the data more
usable.(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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were selected from a pool of over seventy applicants ﬁve teams.1 In
addition to the tranSMART platform, various third-party analytic
tools were employed, including MetaCore™, R interface, Spotﬁre,
E-Workbook, MatLab, and REFS™.
3. Approaches & results
Each team applied a distinctive and innovative approach to explora-
tion and analysis of these data. The sum of their ﬁndings validated the
feasibility of their approaches and suggest possible new approaches
for the research community to adopt in studying these diseases.
Team 1: Challenge: Identify novel biomarkers that predict progres-
sion of Parkinson's disease using the PPMI dataset. Team members
sought to 1) identify signiﬁcant SNPs, and SNP interactions, that predict
progression of Parkinson's disease, and 2) evaluate the implications of
ﬁndings for an improved understanding of the biology of the disease
as well as for better clinical trial design..
They assessed the data to construct a data frame to model key vari-
ables in the database. This included the data frame composition,
transforming outcome variables of Parkinson's Progression and evaluat-
ing the genetic data pipeline. The genetic data pipeline identiﬁed 210k
SNPS, with higher criticism statistical pruning revealing 293 MoCA re-
lated SNPS and 108 UPDRS related SNPS. The ﬁnal data frame contained
109 known PD SNPS, with 263 SNPS associated with MOCa scores and
668 SNPS associatedwith UPDRSI-III scores. Diverse rates of progression
were found.
REFS™Machine Learning was employed to do predictive analytics
and build a model to predict the rate of change for MOCA decline.
REFS™model building proceeded in three steps: enumeration, optimi-
zation and simulation, to predict variables and relationships that
inﬂuence outcomes.
Findings:
• Several genetic markers and one epistatic interaction were found to
have stronger network consensus than age of onset.
• SNP that has an association with Multiple Sclerosis severity
• SNP that has an association with brain cancer
• ASNP associatedwith both Parkinson's Disease andAlzheimer disease
• Evidence for a conditional epistatic interaction.
Conclusion:
Newly identiﬁed genetic markers can explain Parkinson's disease
rate of progression. The identiﬁed epistatic interaction enables im-
proved patient groupings and enhanced risk proﬁles. Continued work
would ideally include RNA data and multi-modal omics, both of which
would deepen biological understanding of rate of progression.
Team 2: Challenge: To Build Disease Proﬁles for Parkinson's disease
and Alzheimer disease through Biomarker Signatures Discovery. The
overall aim was to identify neurodegenerative disease signatures and
proﬁles in pre-symptomatic Parkinson's disease and Alzheimer disease.
Speciﬁcally, the group sought to identify biomarkers that distinguish
pre-symptomatic from normal individuals and map a unique stage of
disease signature to prodromal and patient populations, both for the1 Team One: Jason Eshleman, IO Informatics, Boris Hayete, GNS Healthcare, Matthew
Valko, GNS Healthcare, Vasco Verissimo, University of Luxembourg, Daniel Weaver,
PerkinElmer, Team Two: Hiroko Dodge, University of Michigan, Ken Kubota, Michael Jay
Fox Foundation, Thomas Misko, Takeda, Venkata Satagopam, University of Luxemoborg, Ve-
nus So, Roche, Jieping Ye, University of Michigan, Team Three: Milan Ganguly, IDBS, Andrew
Krueger, Takeda, Adam Palermo, Sanoﬁ, Jose Cruz, IO Informatics, Jian Zhu, University of
Michigan, Team Four: Eric Aslakson, Poiema, LLC, Ivo Dinov, University of Michigan, Mark
Frasier, Michael Jay Fox Foundation, Eugene Myshkin, Thomson Reuters, Alexandria Papa,
Pﬁzer, Alex Yuzhakov, Ulon (Akson Pharmaceuticals), TeamFive: Christian Ebeling, Fraunho-
fer Institute for Algorithms and Scientiﬁc Computing (SCAI), Zhuma Feng, Biogen, Pinghua
Gong, University of Michigan, Wei Gu, University of Luxembourg, Jong-min Lee, Massachu-
setts General Hospital/Harvard University, Janneke Schoots van der Ploeg, The Hyve.purpose of developing a pre-symptomatic diagnostic that is less expen-
sive than the current imaging technologies.
Findings:
1. Analysis of ADNI data found that converters display high cerebral
spinal ﬂuid (CSF) T-Tau levels and lower precuneus thickness.
2. Potential new biomarker signatures for neurodegenerative disease,
shared by Parkinson's disease and Alzheimer's disease, are:
• CSF total Tau is signiﬁcantly higher in Alzheimer's disease patients
versus controls while 〈-Synuclein levels are the same as healthy
controls
• PD patients have lowermonocyte level than prodromal and healthy
controls
• PD patients and prodromals have higher levels of neutrophils than
healthy controls.
3. Differentially expressed genes are markers of underlying pathology
in Alzheimer's disease
• Differential expression between normal_normal and normal_MCI
(mild cognitive impairment) appears to be:
i. Potential biomarkers
ii. Contributors to disease process.
• Differential expression was found in non-coding RNA, transcription
factors and Wnt signaling pathways
4. Overlaying differential expression genes on the Parkinson disease
map revealed two areas of mitochondrial dysfunction.
Conclusion: These ﬁndings are valuable and should be extended by
further research. With added data content, further data mining is likely
to identify important as yet unknown results.
Team3: Challenge: Investigatewhether there's anything in common
between Gene Expression Analysis of PD and AD Blood Samples. The
group explored data in the tranSMART platform to formulate their
hypotheses and generate its approach to investigating possible com-
monalities between themolecular data, including pathways, and corre-
lations between expression and clinical outcome. They found that
PIP4K2A blood expression is lower in both PD and ADNI dementia.
Applying Thomson Reuter's tools for pathway analysis pointed to
TGF-Beta and SMAD3 as key players. Further, direct interactions of
PD/AD pathway-enriched genes were observed.
Findings:
1. The TGFb pathway is altered in the whole blood of both PD and AD
patients
2. LARGE transcript expression correlates with 20% slower increasing
likelihood of developing dementia.
Conclusion: Based on these results, proposed next steps are to
examine integrated gene signature of the TGBf pathway activity and
to correlate TGBf pathway and LARGE expressionwith clinical outcome.
Team 4: Challenge: To identify a gene signature that differentiates
Parkinson's disease from healthy normals and to compare ﬁndings
with Alzheimer's disease. The group explored GEO studies of whole
blood and post mortem brain samples in search of a shared biomarkers
that could differential PD from healthy subjects. Expression data from 8
studies were retrieved with tranSMART R-client and assembled into a
single matrix. The analysis sets the following parameters: expression
data were presented by tranSMART as z-scores, fold changes were
approximated as the difference of z-score means between cohorts,
loose thresholds were used so that an adequate number of genes were
considered to permit evaluating overlap interactions between several
studies. The gene signiﬁcance was inferred from the number of studies
the gene was differentially expressed in.
It was revealed by pair wise comparison of the number of common
differentially expressed genes for each study that this is a signiﬁcant
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on brain samples. Yet there was almost no overlap between the
differentially expressed genes from blood samples with brain samples,
indicative of the role of blood brain barrier and suggesting that
researchers should be careful when using blood biomarkers as predic-
tors for brain diseases.
The top differentially expressed genes found common to all 8 studies
under investigation were: RBX1 (RING-box protein 1), RIOK3 (serine/
threonine-protein kinase RIO3), UCHL1 (ubiquitin carboxyl-terminal
esterase L1) and UGP2 (UDP-glucose pyrophosphorylase 2). Of them,
only UCHL1 was previously reported in the literature to be associated
with PD, the other three genes can be considered novel PD biomarkers
never before associated with it. 534 genes were differentially expressed
in at least six studies.
Pathway enrichment analysis with MetaCore™ software indicated
that this 534 gene signature is enriched with pathways speciﬁc for neu-
rodegenerative diseases and PD. The top pathways involved were oxi-
dative phosphorylation, neuroﬁlament cytoskeleton remodeling
dynein–dynactin motor complex in an axonal transport. Among the
top pathways also enriched with over connected hubs, that can be
considered upstream regulators of that gene signature, as suggested
by MetaCore™ Key Pathway Advisor, was the “LRRK2 in neurons in
Parkinson's disease”. Interestingly, LRRK2 is the most commonly
known genetic cause of PD and a number of genes from that 534 gene
signature are involved in its signaling.
Findings:
1. The 534 gene signature is enriched with genes associated with neu-
rodegenerative diseases in general and LRRK2 signaling in particular
2. Many genes not yet identiﬁed as associatedwith PD are in fact poten-
tial novel biomarkers.
3. These results can be applied to subtype Alzheimer's patients. A
subset of the 534 gene signature when applied to blood sample
data from ADNI was able to differentiate between two cohorts,
which have yet to be identiﬁed.
The team formulated a second project to categorize PPMI subjects
through the use of clinical data in the PPMI tranSMART dataset, includ-
ing additional brain shape information derived by the neuroimaging
biomarker dataset from the PPMI cohort.
Conclusion: This second project is currently ongoing and is evaluat-
ing dystonia and dyskinesia as a measure of disease severity compared
to brain shape information.
They intend to perform a latent class analysis followed by a statisti-
cal validation of the clinically derived subgroups against SNPs.
Team5: The team compared differential gene expression for PD ver-
sus controlswithmicroarray data and checked the effects of those genes
in AD. The goal was to identify biomarkers that are associated with
triggering the same etiologies in hopes of identifying causes of rapid
progression. The team evaluated the top 100 differentially expressed
markers in each study and checked the markers that are shared by at
least two studies. They looked extensively at the genes that are also
differentially expressed in AD (ADNI dataset) as well as one gene that
shows differences in both brain tissue and blood.Findings:
• 16 biomarkers were identiﬁed from at least 2–3 different studies
• 1 biomarker was identiﬁed from 2 studies evaluating both blood sam-
ple and brain tissue samples, indicating a potential diagnostic marker
• Both the PD and AD data sets showed biomarkers associated with the
same triggering etiology.
Conclusion: Further evaluation of shared biomarkers associatedwith
triggering etiology is a promising research strategy.
4. General observations on the Datathon
4.1. Lessons learned
Several teams used the tranSMART platform for data browsing and
patient cohort selection, and then downloaded and exported data ﬁles
to other analytical tools outside the platform. Others used the built-in
analytics for most or all of their analysis. Some noted speciﬁc data
collection needs that will improve data analysis capabilities, such as
the noted absence of CSF in the PD prodromal cohort.
5. Conclusion
Bringing data scientists, neuroscientists and biostatisticians together
to leverage a large, integrated cross-neurodegenerative disease dataset
in tranSMART validated the utility for the platform, and the value of
these data when integrated. The Datathon produced an innovative ap-
proach using machine learning, new biomarker ﬁndings, and scientiﬁ-
cally thorough pathway analyses. It also successfully demonstrated
that data sharing and the Datathon approach in particular can expedite
discovery, as well as offer new fruitful ways to explore datasets. These
new approaches are available for the research community to adopt.
Further, the event demonstrated that the tranSMART Platform can
support many different large and distributed datasets as well as meet
varied end-user needs simultaneously. Theplatform's ability to organize
these datasets in useful fashions enabled participants to generate new
ﬁndings and approaches for future research. In doing so, the Platform
proved to be a powerful tool in expediting research in a cost efﬁcient
way. The value of bringing together experts from different disciplines
and organizations to work in newly formed teams on integrated
datasets deployed in the tranSMART platform was evident. The
Datathon also provided excellent technical and scientiﬁc feedback on
how to improve the tranSMART platform for use by the research
community in real scientiﬁc projects. Finally, all 5 teams stated that
they intended to continue the work started at the Datathon, and to
continue to work with their Datathon team members.
Thank you to our sponsors, IDBS, PerkinElmer and Thomson Reuters
for helping make the Datathon happen.
